D. Boral Capital Reaffirms "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX)

D. Boral Capital reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $32.00 target price on the stock.

A number of other equities analysts have also recently commented on CMPX. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Monday, November 11th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. Leerink Partnrs cut shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $11.80.

Compass Therapeutics Stock Up 30.1 %

Compass Therapeutics stock traded up $0.43 during mid-day trading on Wednesday, reaching $1.86. 24,184,620 shares of the company's stock traded hands, compared to its average volume of 5,235,235. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.68. The stock has a 50 day moving average of $1.56 and a two-hundred day moving average of $1.44. The company has a market cap of $255.92 million, a price-to-earnings ratio of -5.03 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. As a group, sell-side analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently made changes to their positions in CMPX. Rovin Capital UT ADV bought a new stake in shares of Compass Therapeutics in the third quarter valued at about $25,000. Intech Investment Management LLC bought a new stake in shares of Compass Therapeutics in the 3rd quarter valued at about $30,000. XTX Topco Ltd purchased a new stake in shares of Compass Therapeutics in the 3rd quarter worth approximately $37,000. Cubist Systematic Strategies LLC bought a new position in shares of Compass Therapeutics during the second quarter valued at approximately $41,000. Finally, SG Americas Securities LLC increased its holdings in Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock valued at $71,000 after buying an additional 5,515 shares during the period. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.